Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to ...

Researchers have discovered that newborns have high levels of the tau protein, which is elevated in older people with Alzheimer’s disease, but that it causes them no harm. The discovery opens the door ...

This Brush Up is sponsored by Quanterix. Learn more about tau biomarkers and clinical applications. Tau is a flexible protein that stabilizes the internal structure of neurons and supports ...

Researchers hope to launch human clinical trials in their quest for a vaccine to prevent the buildup of pathological tau after demonstrating that this vaccine generated a robust immune response in ...

With two new treatments for Alzheimer’s disease approved in recent years, there’s growing hope for people at risk of the memory-robbing condition. But tests to detect the condition still lag behind.

An installation view of “Tau Lewis: Spirit Level” at David Zwirner Los Angeles. Photo by Elon Schoenholz / Courtesy David Zwirner For her debut show with David Zwirner, Tau Lewis transformed the Los ...

For years, the Alzheimer’s disease field has been on a quest for the perfect blood marker. Such a test could spare patients from invasive lumbar punctures, broaden care access, and allow AD cases to ...

Detecting toxic forms of tau before they weave into dense thickets of tangles could pave the way for earlier diagnosis and treatment of tauopathies, including Alzheimer’s disease. In the February 10 ...

A biomarker test identified tau pathology in Alzheimer's disease before fibrillary tangles developed. Neurofibrillary tangle formation can be prevented by targeting intermediate soluble tau assemblies ...

Artur is a copywriter and SEO specialist, as well as a small business owner. In his free time, he loves to play computer games and is glad that he was able to connect his professional career with his ...